Which sleep aids are not considered potentially inappropriate according to the Beers criteria for older adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sleep Aids NOT on Beers Criteria for Older Adults

The sleep aids that are NOT considered potentially inappropriate according to the 2019 AGS Beers Criteria include: low-dose doxepin (≤6 mg), ramelteon, and suvorexant. 1, 2

Acceptable Sleep Medications

Based on the most recent Beers Criteria guidelines, the following agents can be used in older adults:

  • Low-dose doxepin (≤6 mg): Specifically at this low dose, it avoids the anticholinergic burden that makes higher doses (>6 mg) potentially inappropriate 2
  • Ramelteon: A melatonin receptor agonist that does not carry the same risks as benzodiazepines 2
  • Suvorexant: An orexin receptor antagonist that is considered acceptable for short-term use 2

Medications to AVOID (On Beers Criteria)

The following are explicitly flagged as potentially inappropriate in the Beers Criteria:

  • All benzodiazepines (including triazolam and temazepam): Despite being mentioned in some treatment guidelines, these carry substantial risks of falls, fractures, cognitive impairment, delirium, motor vehicle accidents, and physical dependence in older adults 1
  • Non-benzodiazepine receptor agonists (Z-drugs): Such as zolpidem, zaleplon, and eszopiclone - these have similar adverse effects to benzodiazepines including increased fall risk and cognitive impairment 1, 2
  • Anticholinergic medications: These increase risk of delirium and cognitive decline 1
  • Doxepin >6 mg: Higher doses have problematic anticholinergic effects 2

Important Clinical Caveats

A critical pitfall: While trazodone and mirtazapine are commonly used off-label for insomnia in older adults and are not explicitly listed on the Beers Criteria, recent 2025 data suggests they may be safer alternatives than quetiapine. Low-dose quetiapine for insomnia showed significantly increased mortality (HR 3.1), dementia (HR 8.1), and falls (HR 2.8) compared to trazodone 3. Though not formally endorsed by Beers Criteria as appropriate, trazodone and mirtazapine appear to be safer off-label options when FDA-approved alternatives are not suitable.

First-line approach: Nonpharmacologic interventions (sleep hygiene and cognitive behavioral therapy) should be attempted before any medication 2. When medications are necessary, they should be used short-term only with frequent monitoring for adverse events including falls, cognitive changes, and motor impairment 2.

References

Research

Therapy Update for Insomnia in the Elderly.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.